SCHEMBL7079355

SCHEMBL7079355

Cc1ccc(C(=O)NN2CCOCC2)c(Nc2ccc3cn[nH]c3c2)n1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 7/20 0.51
PDGFRA P16234 7/20 0.51
KDM4E B2RXH2 3/20 0.48
LMNA P02545 3/20 0.48
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
MAPT P10636 1/20 0.48
ADORA2A P29274 1/20 0.47
ROCK2 O75116 1/20 0.47
ROCK1 Q13464 1/20 0.47
MAOB P27338 1/20 0.46
SYK P43405 4/20 0.46
USP2 O75604 1/20 0.43
MAPK1 P28482 1/20 0.43
HSD17B10 Q99714 1/20 0.43
BTK Q06187 2/20 0.43
KDR P35968 1/20 0.42
TRPV1 Q8NER1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7077421 0.93 ROCK2 (0.55) PDGFRBPDGFRAADORA2AROCK2ROCK1
SCHEMBL7077567 0.90 PDGFRB (0.52) PDGFRBPDGFRAKDM4ELMNANPC1
SCHEMBL7078745 0.87 PDGFRB (0.52) PDGFRBPDGFRAKDM4ELMNANPC1
SCHEMBL7077905 0.85 PDGFRB (0.67) PDGFRBPDGFRAKDM4ELMNANPC1
SCHEMBL7081452 0.82 SYK (0.50) PDGFRBPDGFRAKDM4ELMNANPC1
SCHEMBL7081454 0.79 SYK (0.53) KDM4ELMNANPC1RAB9ASMN1; SMN2
SCHEMBL7082077 0.79 SYK (0.52) PDGFRBPDGFRAKDM4ELMNANPC1
SCHEMBL7077410 0.79 SYK (0.52) KDM4ELMNANPC1RAB9ASMN1; SMN2
SCHEMBL7083647 0.79 SYK (0.48) PDGFRBPDGFRAKDM4ELMNANPC1
SCHEMBL7200481 0.79 PDGFRB (0.46) PDGFRBPDGFRAKDM4ELMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608058-B2 Therapeutic composition for hepatitis B, hepatitis C, or acquired immune deficiency syndrome DONG WHA PHARM. IND. CO., LTD. (KR) 2003-08-19 US claimed
US-20030092709-A1 6-Methylnicotinamide derivatives as antiviral agents DONG WHA PHARM. CO., LTD. (KR) 2003-05-15 US claimed
US-6608058-B2 Therapeutic composition for hepatitis B, hepatitis C, or acquired immune deficiency syndrome DONG WHA PHARM. IND. CO., LTD. (KR) 2003-08-19 US disclosed
US-20030092709-A1 6-Methylnicotinamide derivatives as antiviral agents DONG WHA PHARM. CO., LTD. (KR) 2003-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030092709-A1 6-Methylnicotinamide derivatives as antiviral agents TPMT, HAVCR2, NNMT PDGFRB 3908/4885PDGFRA 3543/4885KDM4E 1288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.